Cryoport Systems Welcomes Chris LaGullo as Chief Operating Officer 

As advanced therapies become more complex and move closer to broader commercial adoption, life sciences organizations are navigating increasingly sophisticated supply chains. From maintaining product integrity across global networks to navigating evolving regulatory requirements, success depends on a supply chain partner capable of delivering consistent, reliable operational execution across the product lifecycle. 

To continue supporting evolving industry needs, Cryoport Systems is pleased to welcome Chris LaGullo as Chief Operating Officer. 

Chris brings more than 20 years of executive leadership experience in global supply chain, logistics, distribution, and operations management across the life sciences and healthcare industries. Throughout his career, he has led complex operations for organizations including Unimed, Marken, Teva Pharmaceuticals, Merck, ConvaTec, Bristol-Myers Squibb, and Philips. Most recently, he served as Chief Operating Officer at Unimed, where he oversaw global distribution center operations, purchasing, compliance, inventory management, and customer delivery functions across multiple international regions. Prior to that, he served as Vice President, Americas at Marken, leading operations that supported time-critical clinical trials, including cell and gene therapy programs.  

“Chris is a highly accomplished supply chain leader with a deep understanding of the unique challenges facing life sciences organizations today,” said Mark Sawicki, Ph.D., President and Chief Executive Officer of Cryoport Systems. “As our clients’ needs and the broader advanced therapy industry continues to evolve, Chris’s expertise in scaling global operations and supporting complex product lifecycles is invaluable in helping therapies reach patients around the world.”  

Chris joins Cryoport Systems at an important time for the industry as advanced therapies become more personalized, manufacturing networks become more distributed, and commercialization strategies expand globally. Supply chain partners play a crucial role in mitigating risk, and Chris’s expertise reinforces Cryoport Systems’ position as the trusted partner life sciences organizations rely on to deliver supply chain certainty when it matters most.  

As Chief Operating Officer, Chris will lead Cryoport Systems’ worldwide network of Global Supply Chain Centers, Global Logistics Centers, and BioServices operations. His leadership will help advance the company’s integrated end-to-end supply chain offering, which combines temperature-controlled logistics, biostorage, custom kit production, drug packaging & labeling, and specialized advisory solutions to support critical materials and therapies from research and clinical development through commercialization.  

At Cryoport Systems, every supply chain decision supports a larger mission. Behind each therapy is a complex journey that requires expertise, coordination, and an unwavering commitment to quality. Ultimately, every operational decision supports the development and delivery of therapies intended to improve patients’ lives. Our mission is to ensure those therapies are available where they are needed, when they are needed, so patients have the opportunity to receive potentially life-changing treatments.  

Chris’s leadership will bring additional depth and expertise to the global capabilities that support our clients as they advance complex therapies. As the life sciences industry continues to evolve, Cryoport Systems remains committed to providing the integrated supply chain solutions, specialized expertise, and global capabilities required to help bring innovative therapies to patients around the world.